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Abstract
Aims Cardiac involvement in sarcoidosis is reported in up to 30% of patients. Left ventricular involvement demonstrated by
contrast-enhanced cardiac magnetic resonance has been well validated. We sought to determine the prevalence and
distribution of right ventricular late gadolinium enhancement in patients diagnosed with pulmonary sarcoidosis.
Methods and results We prospectively evaluated 87 patients diagnosed with pulmonary sarcoidosis with contrast-enhanced
cardiac magnetic resonance for right ventricular involvement. Pulmonary artery pressures were non-invasively evaluated with
Doppler echocardiography. Patient characteristics were compared between the groups with and without right ventricular
involvement, and right ventricular enhancement was correlated with pulmonary hypertension, ventricular mass, volume,
and systolic function. Left ventricular late gadolinium enhancement was demonstrated in 30 patients (34%). Fourteen patients
(16%) had right ventricular late gadolinium enhancement, with sole right ventricular enhancement in only two patients. The
pattern of right ventricular enhancement consisted of right ventricular outﬂow tract enhancement in 1 patient, free wall
enhancement in 8 patients, ventricular insertion point enhancement in 10 patients, and enhancement of the right side of
the interventricular septum in 11 patients. Pulmonary arterial hypertension correlated with the presence of right ventricular
enhancement (P < 0.001). Right ventricular enhancement correlated with systolic ventricular dysfunction (P < 0.001),
hypertrophy (P = 0.001), and dilation (P < 0.001).
Conclusions Right ventricular enhancement was present in 16% of patients diagnosed with pulmonary sarcoidosis and in
48% of patients with left ventricular enhancement. The presence of right ventricular enhancement correlated with pulmonary
arterial hypertension, right ventricular systolic dysfunction, hypertrophy, and dilation.
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Introduction
Sarcoidosis is a rare, inﬂammatory condition, resulting
from an uncontrolled cellular inﬂammatory response in
genetically predisposed individuals, which affects the heart
in approximately a third of patients.1 Left ventricular
involvement demonstrated by contrast-enhanced cardiac
magnetic resonance has been well validated.2 Until recently,
limited attention has been given to right ventricular
involvement in cardiac sarcoidosis, its prevalence, relevance,
and prognostic value.3 Cardiac magnetic resonance imaging
is the preferred imaging tool to evaluate the healthy and
diseased right ventricle.4,5 Right ventricular volumes, mass,
and function can be quantiﬁed without geometric
assumptions and excellent intra-observer and inter-observer
agreement and inter-study reproducibility.4–6 Delayed
contrast-enhanced magnetic resonance allows for the
detection and quantiﬁcation of focal scar and interstitial
ﬁbrosis. Although there are numerous reports on delayed
contrast-enhanced cardiac magnetic resonance delineating
left ventricular sarcoidosis, relatively few studies have
reported on right ventricular involvement.3,7–10 We sought
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to determine the prevalence and distribution of right
ventricular late gadolinium enhancement in patients
diagnosed with pulmonary sarcoidosis and determine the
relationship with pulmonary hypertension, ventricular
volume, mass, and systolic function.
Methods
Patient selection
Between July 2001 and March 2014, we enrolled 87
consecutive patients with histologically proven pulmonary
sarcoidosis. Cardiac evaluation was performed because of
symptoms or routine screening to exclude cardiac
involvement. Patients were excluded when the standard
contra-indications for contrast-enhanced cardiac magnetic
resonance existed. Institutional Review Board approval was
obtained for this study.
Baseline investigations
Baseline investigations included 12-lead electrocardiography,
Doppler echocardiography, and contrast-enhanced cardiac
magnetic resonance. Pulmonary artery systolic pressure was
estimated from the tricuspid regurgitant velocity plus an
estimate of right atrial pressure derived from the inferior vena
cava.11 Right-sided heart studies12 were performed in patients
with pulmonary hypertension and congestive heart failure
and in patients in whom automated cardioverter deﬁbrillators
were implanted. Coronary angiography was performed to
exclude underlying coronary artery disease in patients with
documented ventricular tachy-arrhythmias, pathological
Q-waves, impaired systolic function, regional wall motion
abnormalities, and/or late gadolinium enhancement.
Cardiac magnetic resonance protocol and analysis
Studies were performed using a commercial 1.5 T scanner
with a cardiac-dedicated phased-array coil. The cardiac
magnetic resonance studies were electrocardiographically
triggered by standard software. Studies consisted of
multi-phase multi-slice steady-state-free precession and
fat-saturated T2-weighted (69) breath-hold sequences of
the short axis, vertical long axis, and horizontal long axis
views. Outﬂow tract views were generated in patients with
right ventricular abnormalities. The short-axis images covered
the left ventricle from base to apex. The steady-state-free
precession sequences (typical repetition time 3.5 ms; echo
time 1.4 ms; ﬂip angle 55°; temporal resolution 50 ms; voxel
size 1.6 × 1.6 × 10 mm, no gap) were performed to assess
regional wall-motion abnormalities, left and right ventricular
masses, volumes, and ejection fractions. Papillary muscles
were included when determining right ventricular mass
and excluded when determining volumes. Contrast-
enhanced and T2-weighted images were obtained in diastole
Table 1 Characteristics of patients with and without right ventricle
late gadolinium enhancement
Patients without
RV LGE
n = 73
Patients with
RV LGE
n = 14 P value
Male 48 (66) 9 (64) 0.779
Caucasian 58 (79) 8 (57) 0.074
Age (years) 52.8 ± 10.2 55.7 ± 9.1 0.460
Cardiac presentation 18 (25) 10 (71) <0.001
Syncope 4 (5) 1 (8) 0.564
Palpitations 7 (10) 3 (21) 0.167
Clinical congestive
heart failure
4 (5) 6 (43) 0.001
Sustained ventricular
Tachycardia
6 (8) 4 (29) 0.039
Chest discomfort 2 (3) 1 (8) 0.388
Dyspnoea
NYHA 0–2 72 (98) 12 (86) 0.388
NYHA 3–4 2 (3) 1 (7) 0.388
Diabetes mellitus 3 (4) 0 1.000
Hypertension 7 (10) 0 0.588
Medication at any time 51 (70) 12 (86) 0.102
Steroids 5 (7) 2 (14) 0.280
Methotrexate 5 (7) 5 (36) 0.006
Loop diuretics 5 (7) 6 (43) 0.001
Spironolactone 5 (7) 7 (50) <0.001
Ace inhibitors/ATIIRB 7 (9) 7 (50) 0.001
Beta blockers 9 (12) 6 (43) 0.008
Amiodarone
Abnormal ECG 18 (25) 10 (71) <0.001
Pulmonary hypertension 5 (7) 9 (64) <0.001
CMR imaging parameters
LVEF, % 60 [54–66] 50 [42–58] 0.015
LVEF ≤ 50% 8 (11) 5 (36) 0.039
LVEDV, mL 113 [90–136] 134 [81–187] 0.261
LVEDV index, mL/m2 58 [47–69] 75 [70–100] 0.142
LV mass 112 [72–152] 122 [83–161] 0.550
LV mass index, g/m2 64 [44–84] 65 [38–92] 0.780
LVH 20 (27) 3 (23) 0.747
LV dilation 5 (8) 4 (29) 0.035
LV LGE 18 (25) 12 (86) <0.001
LV LGE, % 12 [4–20] 28 [18–38] 0.002
RVEF, % 49 [43–55] 33 [24–42] 0.001
RVEDV, mL 148 [108–188] 188 [141–235] 0.034
RVEDV index, mL/m2 78 [58–98] 96 [68–124] 0.018
RVESV 72 [47–97] 102 [70–134] 0.05
RVESV index, mL/m2 37 [26–48] 58 [38–78] 0.046
RVH 5 (7) 6 (43) 0.001
RV mass, g 42 [34–50] 53 [35–71] 0.068
RV mass index, g/m2 21 [17–25] 28 [22–34] 0.075
RV dilation 3 (4) 6 (43) <0.001
RVEF ≤ 45% 6 (8) 10 (71) <0.001
T2 positive 7/60 (12) 3/9 (33) 0.112
CI, conﬁdence interval; CMR, cardiac magnetic resonance; EDV,
end-diastolic volume; LGE, late adolinium enhancement; LV, left
ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left
ventricular ejection fraction; RV, right ventricle; RVEDV, right
ventricular end-diastolic volume; RVEDVI, right ventricular end-
diastolic volume index; RVEF, right ventricular ejection fraction;
RVH, right ventricular hypertrophy.
Bold signiﬁes signiﬁcance i.e. P < 0.05.
Values are n (%), median [IQR], or mean ± SD.
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to minimize artefact due to cardiac motion. Ten minutes
after the additional administration of 0.1 mmol/kg
gadolinium-diethylenetriaminepenta-acetic acid (Schering,
Berlin, Germany), a two-dimensional segmented inversion
recovery-gradient echo breath-hold sequence (short axis,
vertical long axis, horizontal long axis, and right
ventricular outﬂow tract in selected patients, voxel size
1.6 × 1.6 × 10 mm, without gap) was used to assess for late
gadolinium enhancement. The inversion time (250 to
400 ms) was determined on an individual basis to obtain
optimal nulling of the unenhanced myocardial signal. Two
experienced, blinded, and independent observers used
commercially available software (CAAS MRV 3.4, Pie Medical
Imaging, Maastricht, the Netherlands) to determine the
standard parameters delineated in Table 1. The distribution
of right ventricular late gadolinium enhancement was
determined by consensus and characterized as free wall,
apical, outﬂow tract, right-sided interventricular septal,
and/or including the ventricular insertion points. Late
ventricular gadolinium enhancement was considered present
only if conﬁrmed on both short-axis and matching long-axis
myocardial locations. Late left ventricular gadolinium
enhancement was quantiﬁed by a semiautomatic detection
method using the signal intensity threshold of ≥2 SD above
a remote reference region. The intra-observer and inter-
observer variabilities were determined by calculating the
variability coefﬁcients and intra-class correlations for each
parameter in 18 randomly selected studies.
Variables and deﬁnitions
Peak systolic right ventricular pressures over 35 mmHg were
considered to represent pulmonary hypertension. Right
ventricular hypertrophy was deﬁned as right ventricular
weight exceeding normal values as published by Maceira
et al. and/or right ventricular end-diastolic wall thickness
over 5 mm.6 Right ventricular systolic dysfunction was
deﬁned as an ejection fraction below 45%.13
Statistical analysis
All statistical analyses were performed using statistical
software (Version 21.0, SPSS; Chicago, IL, USA). Continuous
normal distributed variables were expressed as mean ± SD
and, between group comparisons, were made using the
parametric t-test for independent samples or the Mann–
Whitney test when appropriate. In the non-normally
distributed continuous data, the median and interquartile
range were determined and, between group correlations,
were made with the Wilcoxon test. Categorical variables were
assessed using the χ2 or Fisher’s exact test when appropriate.
Statistical signiﬁcance was deﬁned at P < 0.05.
Results
Patient characteristics
Table 1 demonstrates the baseline characteristics in the
included 87 patients. Twenty-seven (31%) patients presented
with cardiac symptoms, while the remaining 60 either
suffered from non-speciﬁc symptoms or were routinely
screened for cardiac sarcoidosis. According to the
ACC/AHA/HRS 2008 guidelines for device-based therapy of
cardiac rhythm abnormalities, an implantable cardioverter
deﬁbrillator or pacemaker was implanted in respectively 14
and 3 patients after the baseline cardiac magnetic resonance
study.14 All had late gadolinium enhancement and suffered
from cardiac symptoms. When applying the recently
Table 2 Characteristics of patients with right ventricle late gadolinium enhancement
Enhanced
segments
Patients
(n = 14)
Combination of
enhanced segments
Patients
(n = 14)
Patients with
pulmonary hypertension
Patients with end-systolic
septal shift (n = 5)
RV septal 11 RV septal 1 1 0
VIP
RV free wall
RVOT
VIP 10 RV septal 3 2 1
VIP
RV free wall
RV free wall 8 RV septal 4 1 0
VIP
RVOT 1 RV septal 2 2 1
RV free wall
RV septal 1 1 1
RV free wall 1 0
VIP 1 1 1
RV free wall 1 0 0
VIP
RV, right ventricular; RVOT, right ventricular outﬂow tract; VIP, ventricular insertion points.
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published Heart Rhythm Society expert consensus criteria, we
diagnosed 31 patients (36%) with cardiac involvement.15
Cardiac magnetic resonance analyses
Thirty patients (34%) had left ventricular and 14 patients
(16%) had right ventricular enhancement, with enhancement
limited to the right ventricle in only two patients (2%). The
group of patients with right ventricular enhancement had
signiﬁcantly more extensive left ventricular enhancement
compared with those without (Table 1, P = 0.007). Table 2
describes the distribution of right ventricular enhancement.
Right ventricular enhancement correlated with early diastolic
left-sided septal displacement (P = 0.002), systolic right
ventricular dysfunction (P < 0.001), hypertrophy
(P < 0.001), and dilation (P = 0.009). Fifteen patients had
pulmonary hypertension, eight of which had right ventricular
enhancement. The presence of ventricular insertion point
enhancement (P = 0.007), right-sided septal (P < 0.001),
and right ventricular free wall enhancement (P = 0.016)
correlated with the presence of pulmonary hypertension.
Right ventricular hypertrophy correlated with the presence
of ventricular insertion point enhancement (P = 0.004) and
right-sided septal (P = 0.001), but not with free wall
enhancement (P = 0.076). In ﬁve patients, early diastolic
septal displacement towards the left ventricle was observed,
two of which had insertion point enhancement (P = 0.099),
and three of which had right-sided septal enhancement
(P = 0.013). Neither the chronicity of pulmonary sarcoidosis,
as determined by the time since diagnosis, nor the extent
of lung disease as determined by high-resolution computed
tomography correlated with pulmonary hypertension, right
ventricular systolic function, or myocardial enhancement.
The right ventricular end-diastolic volume index in patients
with pulmonary Stage 4 (ﬁbro-cystic disease) was signiﬁcantly
larger compared with the earlier disease Stage 1 (hilar nodes
only) (P = 0.027). The T2-weighted studies suggested active,
granulomatous disease in only 10/69 (14%) of patients. The
intra-observer variability for right ventricular end-diastolic
volume was 2%, end-systolic volume 3.4%, ejection fraction
3.4%, and mass 4%. The interobserver variability for right
ventricular end-diastolic volume was 1.6%, end-systolic
volume 5%, ejection fraction 3.2%, and mass 8%.
Discussion
This is the ﬁrst prospective cardiac magnetic resonance
study to speciﬁcally report on the prevalence and
distribution of right ventricular involvement in cardiac
sarcoidosis. Predominant or isolated right ventricular
involvement is rare, with nearly all patients suffering from
left ventricular disease.16 With Murtagh et al., Crawford
et al., and Cheong et al., we found more extensive left
ventricular enhancement to be associated with right
ventricular involvement.8,10,17 Previous studies reported a
correlation between the presence and extent of left
ventricular enhancement, impaired left and right ventricular
systolic function, and higher adverse event rates. The direct
relationship between right ventricular enhancement, its size
and systolic function, as previously demonstrated in left
ventricular sarcoidosis, has not been reported before.
Right ventricular enhancement, inﬂammation, and
impaired systolic function have been associated with adverse
outcome, particularly ventricular tachy-arrhythmias.10,17–20
Figure 1 (A) Contrast-enhanced magnetic resonance study in a patient
with biventricular congestive heart failure (inversion-recovery gradient
echo sequence and horizontal long axis view) demonstrates
enhancement of the right ventricular free wall and right-sided
interventricular septum. (B) Short axis view in the same patient
demonstrates enhancement of the right-sided interventricular septum
and inferior right ventricular insertion point.
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However, the localizations of the arrhythmogenic foci were
not reported on. Because right ventricular sarcoidosis occurs
in patients with more extensive left ventricular disease, the
reported prognostic relevance of right ventricular disease
may at least partly reﬂect the extent of left ventricular
arrhythmogenic substrate.
Several post-transplant and post-mortem studies in
sarcoidosis patients have reported right ventricular involve-
ment to range from 6%, in patients dying from alternate
causes, to as high as 65% in those dying from sudden cardiac
deaths.21–25 Generally, patients with congestive failure were
found to have extensive biventricular sarcoid (Figure 1), and
in those who had died suddenly, active granulomatous
inﬁltration and patchy scar were present. Right ventricular
outﬂow tract involvement was rare (Figure 2).
Ten recent studies employing contrast-enhanced
magnetic resonance in the assessment of cardiac
sarcoidosis reported on right ventricular disease in
sarcoidosis (Table 3).3,7–10,17–20,26 Our ﬁndings in an
unselected population with pulmonary sarcoidosis compare.
Right ventricular enhancement was reported in ﬁve of
these studies and ranged from 2% in unselected to 48%
in high-risk populations, which compares with our 47% of
patients with left ventricular sarcoidosis.3,7–10 Similar to
our ﬁndings, nearly all patients with right ventricular
enhancement had left ventricular enhancement. Samar
et al., Patel et al., and Crawford et al. were the only
researchers to report on right ventricular enhancement in
more detail.3,7,10 Contrary to our and other studies, Samar
et al. reported that right ventricular enhancement did not
correlate with a difference in left ventricular ejection
fraction. His data were included in a poster presentation,
which precluded detail, while relevant data were not
available in 19% of patients.3 Crawford reported multi-focal
Table 3 Cardiac magnetic resonance studies reporting on right ventricular involvement in cardiac sarcoidosis
Authors Type of study Patients Conclusion
Cheong et al.8 Prospective, single centre 31 patients asymptomatic biopsy
proven systemic sarcoidosis, 8 (26%)
LV LGE of whom 2 (25%) with
RV LGE, inferobasal
RV LGE in patients with most
LV LGE
Asymptomatic small amount
of LGE (average 3.2% of LV)
in 26%, no cardiac events
after 1 year
Patel et al.7 Prospective, single centre 81 patients with extra-cardiac
sarcoidosis, 21 (26%) with LV LGE
(average 6 g), 14 (67%) had
right-sided septal LGE incl 4 RV
free wall/outﬂow tract/anterobasal
segments
Patients with LGE had 9-fold
higher rate of adverse events
Patel et al.19 Retrospective, single centre 152 patients extra-cardiac
sarcoidosis, LVEF ≥ 50%, 29 (19%)
LV LGE, no data on RV LGE
Patients with LV LGE had
lower RVEF, because of either
presumed biventricular disease
or pulmonary hypertension
Schuller et al.18 Retrospective, multi-centre 112 CS patients with ICDs for
primary or secondary prevention,
no data on LGE
Impaired systolic LV and RV
function correlates with more
ICD therapy
Samar et al. (poster)3 Retrospective, single centre 122 sarcoidosis patients, 37 (22%)
LV LGE, 18 (49%) of these also
RV LGE
LVEF, LVEDV, RVEDV similar in
groups with/without RV LGE
Crawford et al.10 Retrospective, multi-centre 52 CS patients, all LVEF > 35%
32 (62%) with LV LGE of which
13 (41%) also had RV LGE
Multi-focal LGE correlated
with VT/VF, patients with
RV LGE had more extensive
LV LGE
Nadel et al.9 Retrospective, single centre 106 sarcoidosis patients, 32
CS-deﬁned by CMR LGE—32
LV LGE, 2 (6%) RV LGE
LGE only independent
predictor of adverse outcome
Muser et al.20 Prospective, single centre 31 CS patients with VTs
pre-ablation, 23 had CMR,
21 (68%) LV LGE, 11 (35%)
RV LGE, no data on RV
distribution or extent
LGE extent predicted
VT-free survival
Ekström et al.26 Retrospective, single centre 50 CS patients, 48 (96%) with
LV LGE, not reported on RV LGE
LV extent of LGE and RVEF,
correlated with adverse outcome
Murtagh et al.17 Retrospective, single centre 205 patients extra-cardiac
sarcoidosis, LVEF ≥ 50%, 41 (20%)
LV LGE, ≥4 patients with VIP LGE,
no speciﬁc data on RV LGE
For every 1% in LGE burden,
the hazard for an event increased
by 8%; mild impaired RV
dysfunction correlated
with increased event rate
CMR, cardiac magnetic resonance; CS, cardiac sarcoidosis; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular
ejection fraction; RV, right ventricle; RVEF, right ventricular ejection fraction.
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right ventricular enhancement in nearly half of those with
left ventricular enhancement, basal, mid, or apical right
ventricular segments being equally involved.10 Similar to
Crawford et al., the majority of our patients (70%) had
multi-focal right ventricular enhancement. However, most
of our patients had right-sided septal enhancement, similar
to Patel’s ﬁndings.7 Right-sided septal and insertion point
enhancement were related to pulmonary hypertension in
eight of our patients. Crawford et al. and Patel et al.
did not include data on right ventricular or pulmonary
pressures. Compared with Crawford’s population, our
patients with right ventricular enhancement had on
average poorer systolic function and more extensive left
ventricular enhancement.
The presence of right ventricular enhancement correlated
with hypertrophy, dilation, and systolic dysfunction. The
relationship between pulmonary hypertension, right
ventricular hypertrophy, dilation, systolic dysfunction, septal
displacement, and septal and insertion point enhancement
has been demonstrated before12 (Figure 3). Right ventricular
enhancement in sarcoidosis may be caused by direct
granulomatous inﬁltration but also be related to pulmonary
hypertension12 (Figures 1 and 3). Right ventricular
hypertrophy, dilation, dysfunction, and enhancement may
be secondary to pulmonary hypertension and are associated
with worse prognosis.12,27 Pulmonary hypertension is found
in 6–28% of the general sarcoidosis outpatient setting and
Figure 2 Contrast-enhanced magnetic resonance study (inversion-
recovery gradient echo sequence, end-diastolic frame, and short axis
view) demonstrates enhancement of the right ventricular free wall
(arrow), ventricular insertion points (triangles), and right-sided septum
(arrow).
Figure 3 (A) Magnetic resonance study (steady-state-free precession
sequence, horizontal long axis view, and end-diastolic frame)
demonstrates dilation of the right ventricle (RV) and right atrium (RA),
marked right ventricular hypertrophy, with displacement of the
interventricular septum towards the left ventricle; both left ventricle
and atrium are compressed. (B) Contrast-enhanced magnetic resonance
study (inversion recovery-gradient echo sequence, short axis view, and
end-diastolic frame) of the identical patient with pulmonary vascular
sarcoidosis and resulting severe pulmonary arterial hypertension
demonstrates contrast-enhancement of the right ventricular hinge points
(triangles) and free wall (arrows).
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may be secondary to pulmonary ﬁbrosis, angiitis, and/or
congestive heart failure.27 The fact that pulmonary
hypertension in our population did not correlate with disease
extent as determined by computed tomography illustrates
the variety in pathophysiology of this condition in
sarcoidosis.28 Right ventricular dilation, systolic impairment,
and inﬂammation, as demonstrated with positron emission
tomography, in sarcoidosis have been demonstrated to
predict adverse outcome in sarcoidosis.10,13,17–19,26,29
In patients with predominant right ventricular disease,
cardiac sarcoidosis needs to be differentiated from
arrhythmogenic right ventricular cardiomyopathy.
Distinguishing features favouring sarcoidosis consist of an
older age of onset, a non-familiar pattern, wider QRS
complexes, septal involvement with atrio-ventricular
conduction disease, multiple arrhythmogenic foci, par-
ticularly right ventricular apical tachycardia, concomitant
left ventricular disease, and the presence of mediastinal
lymphadenopathy.30 Electro-anatomic mapping, contrast-
enhanced magnetic resonance, and/or positron emission
tomography may guide endomyocardial biopsies needed to
obtain histological conﬁrmation of the diagnosis.
We report on ventricular insertion point enhancement, a
distribution pattern not speciﬁcally mentioned in the other
studies. Late enhancement of the septum and insertion
points may result from delayed wash-out of gadolinium due
to altered myocardial ﬁbre strain, ﬁbre disarray, ischaemia,
and ﬁbrosis, secondary to right ventricular pressure or
volume overload, and resulting septal shift.12,31,32 Ventricular
Figure 4 Contrast-enhanced magnetic resonance study (inversion-
recovery gradient echo sequence and short axis view) in a patient
without pulmonary hypertension demonstrates enhancement of the
ventricular insertion points (arrows), papillary muscles (asterisks), and
postero-lateral left ventricular segments (triangle).
Figure 5 (A) Contrast-enhanced magnetic resonance study (inversion-
recovery gradient echo sequence, end-diastolic frame, and short axis
view) in a patient diagnosed with a high-degree atrio-ventricular block
secondary to active cardiac sarcoidosis. A dual chamber pacemaker had
been inserted. Ventricular insertion point enhancement is demonstrated
(triangles). Pulmonary pressures were normal (asterisk—artefact of right
ventricular pace lead). (B) Contrast-enhanced magnetic imaging study
(inversion-recovery gradient echo sequence, end-diastolic frame, and
short axis view) in the identical patient when reassessed 7 years later
demonstrates substantially more enhancement of the right-sided septum
(arrow) and the insertion points (triangles). The percentage time pacing
had increased from 5% to 15% of the time (asterisk—artefact produced
by right ventricular pace lead).
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insertion point enhancement has been reported in
hypertrophic cardiomyopathy, atrial septal defects, severe
pulmonary hypertension, tetralogy of Fallot, transposition of
the great arteries, and even a proportion of veteran healthy
endurance athletes31–35 (Figures 2–5). The amount of
insertion point enhancement correlates with mean
pulmonary arterial pressures, right ventricular mass, volume,
and ejection fraction.12 Pulmonary hypertension in
sarcoidosis is associated with adverse outcome, particularly
when accompanied by right ventricular dysfunction, and/or
lung ﬁbrosis.12,27 Recently, Swift et al. reported septal
extension of insertion point enhancement in pulmonary
hypertension to mark more severe disease, with associated
right ventricular dilation, but found it not to be an
independent predictor of overall mortality.12
Late gadolinium enhancement includes active, potentially
reversible, granulomatous inﬂammation, and chronic focal
scar.8,20,36 Immune suppressive treatment, currently a work
in progress, may potentially improve systolic function and
decrease arrhythmogenic substrate.10,20,36 The T2-weighted
spin echo-based assessment used in our study to evaluate
for active granulomatous inﬁltration and associated oedema
is rather insensitive.8 T2 mapping and positron emission
tomography have shown promise and will be included in
future projects.28,37
Conclusions
Approximately 30% of an unselected patient population with
pulmonary sarcoidosis had left ventricular involvement, half
of which had right ventricular involvement. More extensive
left ventricular enhancement correlated with right ventricular
involvement. Right ventricular enhancement may result from
direct inﬁltration and resulting scar or pulmonary
hypertension. Previous studies associated impaired systolic
right ventricular function and right ventricular enhancement
with ventricular tachy-arrhythmias. We demonstrate right
ventricular enhancement with cardiac magnetic resonance
to be mostly multi-focal, involve the septum, and correlate
with increased right ventricular volumes, hypertrophy, and
impaired systolic function.
Limitations
Pulmonary pressures were routinely determined non-
invasively in the majority of our patients, and we may have
underestimated the pulmonary pressures. Our imaging
protocol was not primarily adapted to evaluate the right
ventricle, our slice thickness, and potentially suboptimal
myocardial nulling may have resulted in an underestimation
of the presence and extent of right ventricular inﬁltration
and scarring. Because T2 mapping was not performed, we
likely underestimated active granulomatous inﬂammation.
The relatively small number of patients included limits our
ﬁndings and conclusions.
Future focus of development
Customized hybrid approaches including electrocardiography,
ultrasound, positron emission tomography, and contrast-
enhanced magnetic resonance will provide us with more
sensitive, accurate, and comprehensive information on
haemodynamic, electrical, mechanical, and inﬂammatory
characteristics of the atriae and ventricles.
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